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Bmp/SmadThe inhibitory Smad7 acts as a critical suppressor of hepcidin, the major regulator of systemic iron homeosta-
sis. In this study we deﬁne the mRNA expression of the two functionally related Smad proteins, Smad6 and
Smad7, within pathways known to regulate hepcidin levels. Using mouse models for hereditary hemochro-
matosis (Hfe-, TfR2-, Hfe/TfR2-, Hjv- and hepcidin1-deﬁcient mice) we show that hepcidin, Smad6 and
Smad7 mRNA expression is coordinated in such a way that it correlates with the activity of the Bmp/Smad
signaling pathway rather than with liver iron levels. This regulatory circuitry is disconnected by iron treat-
ment of Hfe−/− and Hfe/TfR2 mice that signiﬁcantly increases hepatic iron levels as well as hepcidin,
Smad6 and Smad7 mRNA expression but fails to augment pSmad1/5/8 levels. This suggests that additional
pathways contribute to the regulation of hepcidin, Smad6 and Smad7 under these conditions which do not
require Hfe.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Systemic iron homeostasis is disrupted in the common iron overload
disorder Hereditary Hemochromatosis (HH) that is hallmarked by inap-
propriately low expression of hepcidin, a peptide hormone that controls
plasma iron levels. Lowhepcidin fails to inhibit iron export by ferroportin
[1] and as a consequence, duodenal iron uptake andmacrophage iron re-
lease is increased and excess iron accumulates especially in the liver. HH
is caused by mutations in hepcidin itself [2] or hepcidin activators like
Hfe (MHC class I-like protein) [3,4], transferrin receptor 2 (TfR2) [5–7],
or the bone morphogenetic protein (Bmp) co-receptor hemojuvelin
(Hjv) [8,9]. Recent ﬁndings highlight the critical importance of the
iron-regulated Bmp/Smad signaling pathway in HH and respective dis-
easemodels, in which the activity of the signaling pathway is attenuated
[5,10–15]. The ﬁnding that Bmp6 [16,17] and hepatocytic Smad4 knock-
out mice [18] are also hallmarked by low hepcidin expression and ironZentrum für Biomedizinische
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l rights reserved.overload, further emphasized the important role for Bmp/Smad signaling
for maintaining physiological hepcidin mRNA expression.
The Bmp/Smad signaling pathway is activated by binding of Bmp
cytokines to cell surface type I and type II serine/threonine kinase re-
ceptors, which then induce phosphorylation of receptor-regulated
Smads (Smad1, 5, and 8) [19,20]. Phosphorylated Smad1/5/8 proteins
(pSmad1/5/8) form heteromeric complexes with Smad4 and translo-
cate into the nucleus to regulate the transcription of target genes,
such as hepcidin, Smad6 and Smad7, among others [19,20]. The inhib-
itory Smads, Smad6 and Smad7, block the Tgf-β/Bmp/Smad signaling
pathways in a negative feed-back loop: Smad6 effectively inhibits
Bmp/Smad signaling and only weakly affects the response to Tgf-β,
contrasting the role of Smad7, which efﬁciently inhibits both signal-
ing pathways [21].
Smad6 and Smad7 transcription is also stimulated by various
non-Bmp/Tgf-β ligands, including epidermal growth factor [20],
interferon-γ [22] or tumor necrosis factor-α [23]. More recently,
Smad7 mRNA expression was shown to be regulated by dietary iron
levels in mice [24,25]. Additional work revealed that Smad7 functions
as a potent inhibitor of hepcidin mRNA expression by interfering with
both Tgf-β and Bmp/Smad-mediated signaling pathways [26]. So far,
a role for Smad6 in iron metabolism has not been addressed. In this
study we deﬁne the expression of Smad6 and Smad7 within the
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for HH.2. Material and methods
2.1. Mice
2.1.1. Hfe−/− mice
Mice carrying an Hfe null allele in the C57BL/6J genetic back-
ground were described previously [27]. We housed Hfe−/− and
Wild type (Wt) mice in the barrier facility of the EMBL, Heidelberg.
Twelve Wt (C57BL/6J) and nineteen Hfe−/− female mice were fed
standard chow (Harlan Teklad, containing 336 ppm iron) and were
sacriﬁced for analysis between 8 and 12 weeks of age.
Systemic iron overload was induced in 5 Wt (C57BL/6J) and 5
Hfe−/− female mice by i.p. administration of 5 mg iron dextran solu-
tion (100 μl of a 50 mg/ml solution, containing 50,000 ppm iron,
Sigma Aldrich, Schnelldorf) twice a week beginning from week 5
until week 7 of age (six doses in total) [28]. As a control, 4 Wt
(C57BL/6J) and 4 Hfe−/− female mice received an injection of 0.5 mg
of Dextran 5 solution (100 μl of 5 mg/ml solution, Chemos GmbH,
Regenstauf). Mice were sacriﬁced for analyses at 8 weeks of age. All
mouse breeding and animal experiments were approved by and
conducted in compliance with the guidelines of the Institutional Animal
Care and User Committee of the EMBL.2.1.2. Hfe−/−, Tfr2−/− and compound Hfe/TfR2 mutant mice
Hfe−/−, Tfr2−/− and compound Hfe/TfR2 mutant homozygous
mice were raised on the FVB genetic background and maintained as
previously described [13]. Brieﬂy, Wt and mutant mice were fed stan-
dard chow (Purina 5001, containing 250 ppm iron) ad libitum after
weaning. Dietary iron loading was achieved by weaning mice onto a
diet containing an additional 25,000 ppm of carbonyl iron until the
age of 5 weeks. Mice were sacriﬁced for analyses at 5 weeks of age.
Each group comprised 3–5 male mice.2.1.3. Wt and Hepcidin1−/− mice
Six male Wt mice raised on C57BL/6N or Sv129 genetic back-
ground were fed standard chow (AO3, UAR; containing 200 ppm
iron). Dietary iron loading of C57BL/6N (n=5) and Sv129 (n=4)
was induced by adding 3% carbonyl iron (i.e. 30,000 ppm iron) as re-
duced pentacarbonyl iron to the diet for 3 weeks, as previously de-
scribed [2]. Mice were sacriﬁced for analyses at 11 weeks of age.
Six Hepcidin1−/− mutant males and six littermate control mice
(Hepcidin1+/+), raised on C57BL/6N [2], were fed standard chow
(AO3, UAR; containing 200 ppm iron) and were sacriﬁced for the
analysis at the age of 40 weeks.2.1.4. Hjv−/− mice
Hjv−/− mice were kindly provided by Dr. Arber (Biozentrum,
Department of Cell Biology, University of Basel, Switzerland) [8].
Mice were maintained on a mixed C57/Sv129 genetic background
at the Animal Facility of the University of Heidelberg. Female mice
(6 Hjv−/− mutant and 8 littermate Hjv+/+ control mice), age be-
tween 40 and 48 weeks were analyzed in this study.2.2. Iron assays
Nonheme iron content of liver tissues was analyzed based on the
principles of the method initially described by Torrence and Bothwell.
The method was modiﬁed and scaled to a 96-well plate format as pre-
viously described [27].2.3. RNA extraction, reverse transcription and real-time PCR
Total RNA was isolated from primary mouse hepatocytes, tissues
and human hepatoma cells using Tri-Reagent (MRC Inc.). Two micro-
grams of total RNA was reverse transcribed using the Revertaid H
Minus M-MuLV Reverse Transcriptase (Fermentas) following the
manufacturer's instructions. Quantitative real-time PCR was carried
out in 20 μl reaction volumes using SYBR Green I dye on ABI Prism
7500 (Applied Biosystems, Applera Deutschland GmbH). The mRNA
abundance of the investigated genes was calculated relative to the ex-
pression of the reference gene Gapdh and β-actin. Data were analyzed
using a mathematical model based on the correction for exact PCR ef-
ﬁciencies. Relative mRNA expression normalized to the reference
genes, Gapdh or β-actin, was compared across the mouse strains ana-
lyzed using the delta Ct method and the REST software [29]. Primers
used in the study are listed:
mmHepcidin1 (5′-ATACCAATGCAGAAGAGAAGG-3′ and 5′-AACAG
ATACCACACTGGGAA-3′)
mmGapdh (5′-GTGGAGATTGTTGCCATCAACGA-3′ and 5′-CCCATTC
TCGGCCTTGACTGT-3′)
mmβ-actin (5′-GCTTCTTTGCAGCTCCTTCGT-3′ and 5′-ACCAGCGCA
GCGATATCG-3′)
mmBmp6 (5′-ATGGCAGGACTGGATCATTGC-3′ and 5′-CCATCACAG
TAGTTGGCAGCG-3′)
mmSmad6 (5′-GTTGCAACCCCTACCACTTC-3′ and 5′-GGAGGAGAC
AGCCGAGAATA-3′)
mmSmad7 (5′-GCAGGCTGTCCAGATGCTGT-3′ and 5′-GATCCCCAG
GCTCCAGAAGA-3′)
mmId1 (5′-ACCCTGAACGGCGAGATCA-3′ and 5′-TCGTCGGCTGGA
ACACATG-3′).
2.4. Western blot analysis
Flash-frozen liver tissues were disrupted manually in RIPA lysis
buffer (50 mM Tris–Cl pH 8.0/150 mM NaCl/1% NP-40/0.5% DOC/
0.1% SDS) complemented with protease (Complete Mini (25) ROC
11836153001, Roche Diagnostics, Mannheim, Germany) and phos-
phatase (1 mM Na3O4Va/25 mM NaF/1 mM PMSF, Sigma Aldrich,
Germany) inhibitors. Lysates were incubated on ice for 30 min and
debris was removed by repeated centrifugation at 10,000 g (4 °C).
Protein concentration of the supernatant was determined using the
Pierce 660 nm Protein Assay Kit (Thermo Scientiﬁc Rockford USA)
based on the method of Bradford. Protein extracts were diluted in
6× Laemmli buffer (0.35 Tris–HCl pH 6.8/1.0% SDS/0.6 M DTT/34%
glycerol/bromphenol blue), incubated for 5 min (95 °C) and subjected
to 10–12% SDS-polyacrylamide gel electrophoreses. Proteins were trans-
ferred to Westran S PVDF blotting membranes (Whatman Inc., UK).
Membranes were blocked with 5% non-fat milk (Carl Roth T145.1) in
TBST buffer (20 mM Tris–Cl pH 7.5/137.5 mM NaCl/0.1% Tween20,
Sigma Aldrich, Germany) for 90 min at room temperature and hybrid-
ized with rabbit polyclonal antibodies to phosphorylated-Smad1/5/8,
total Smad1, Smad4 and total Stat3 (all at 1:500; Cell Signaling Tech-
nology, Danvers, MA), and with mouse monoclonal antibody to
phosphorylated-Stat3 (1:500; Cell Signaling Technology, Danvers,
MA) and β-actin (clone AC-15; 1:10,000; 15 min RT, Sigma Aldrich,
Germany) at 4 °C overnight and washed with TBST buffer. Following
incubation with an anti-rabbit (1:5000, Sigma Aldrich, Germany) or
anti-mouse IgG antibody (1:10,000, Sigma Aldrich, Germany) conju-
gated to horseradish peroxidase, enzyme activity was visualized by
treating the membranes with the ECL kit (Perkin Elmer, Waltham
USA), according to the manufacturer's instructions and exposing to
ﬁlm (Amersham Hyperﬁlm ECL, Buckinghamshire, UK).
For Western-blot analysis of proteins prepared from primary he-
patocytes, we used 30 μg of protein extracts which were separated
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Fig. 1. Iron supplementation increases Bmp6, Smad6, Smad7 and hepcidin mRNA ex-
pression in Wt mice maintained on different genetic backgrounds. Wt mice raised on
C57BL/6J genetic background were injected with iron-dextran (n=5) or dextran as
control (n=4) (A). In addition, Wt mice maintained on FVB genetic background
were fed an iron-rich (4 mice/group) or iron-balanced diet (6 mice/group) (B). Hepatic
non-heme iron concentrations (LIC) were measured and expressed as μg of iron per
gram of dried liver tissue. Bmp6, Smad6, Smad7 and hepcidin mRNA was quantiﬁed
by real-time PCR and normalized to the expression of Gapdh. Results are shown as
the mean±S.D.
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nitrocellulose membranes by tank-blot procedure. For detection of
phosphorylated Smad1/3 and Smad2 rabbit polyclonal antibodies
were used (1:500 each, Cell Signaling Technology, Danvers, MA).
Quantitation was performed by densitometry analysis of the im-
munoblot staining intensity (ImageJ; www://rsb.info.nih.gov/ij/).
2.5. Smad6 overexpression in primary murine hepatocytes
Murine primary hepatocytes were isolated from C57BL/6 mice
according to an optimized protocol described previously [30]. Primary
hepatocytes were transduced with adenoviral vector constructs gener-
ously provided by Prof. Heldin and Dr. Moustakas (Uppsala University)
expressing the full-length murine Smad6 gene under the control of the
CMV promoter (AdSmad6) and the β-galactosidase gene as a control
(AdLacZ) in doses ranging between 5×106 and 6×107 infectious parti-
cles/ml. Forty‐eight hours later the primary cultures were treated with
TGFβ (5 ng/ml; for 6 h; Peprotech) and then harvested for the isolation
of total RNA.
2.6. Statistical analysis
Data are shown as mean values±standard deviation (SD). Statistical
analysis was performed using Student t-test (two-tailed; unequal vari-
ance). Statistically signiﬁcant changes are marked by * (p valuesb .05),
** (p valuesb .005), *** (p valuesb .0005), and ns (no signiﬁcant
difference).
3. Results
3.1. Iron overload in wild-type mice triggers the coordinated increase of
hepcidin, Smad6 and Smad7 mRNA expression
Recently, a role for Smad7 as an iron-responsive gene and a nega-
tive regulator of hepcidin expression has been reported [24–26]. By
contrast, a role for Smad6 in this process has not been investigated
so far.
We show that systemic iron injections in C57BL/6J Wt mice and
dietary iron supplementation into Wt mice raised on the FVB genetic
background associate with increased liver iron deposition (LIC) and
increased Bmp6, Smad6, Smad7 and hepcidin mRNA expression
(Fig. 1A, Suppl. Fig. 2A; Suppl. Fig. 1A). Likewise, Wt mice raised on
the C57BL/6N and Sv129 genetic background and maintained on
iron-rich diet show a marked increase in LIC (7.3-fold, pb0.000637 and
10.2-fold, pb0.000689, respectively) [24,25,31] and increasedmRNA ex-
pression of Bmp6, Smad6, Smad7 andhepcidin (Suppl. Fig. 1B,C).We con-
clude that Smad6 and Smad7 are co-regulatedwith hepcidin and Bmp6 in
response to iron overload in Wt mice.
3.2. Loss of Hfe, TfR2, Hfe and Tfr2 or Hjv impairs Smad6, Smad7 and
hepcidin mRNA response to iron
Mice with a functional loss of the HH proteins Hfe, TfR2, Hfe and
TfR2, or Hjv are hallmarked by severe iron overload that associates
with increased hepatic Bmp6 and inappropriately low hepcidin mRNA
levels (Figs. 2A,B, 3A,B, 4A,B; Suppl. Figs. 2C, 3A,C), being consistent
with previous reports [8,10,11,13,14]. The observation that Smad6
and Smad7 are co-regulated with hepcidin and Bmp6 in response to
iron overload in Wt mice prompted us to examine their relationship
in each of murine HH models. While Bmp6 mRNA levels positively as-
sociate with high hepatic iron burden in HH mice, the mRNA expres-
sion of Smad6, Smad7 and hepcidin is inappropriately low in regard
to liver iron levels. Thus, Smad6 and Smad7 mRNA expression are
co-regulated with hepcidin mRNA levels in the mutant mice (Figs. 2B,
3B, 4B; Suppl. Figs. 2C, 3A,C). To substantiate this ﬁnding, we expressed
Smad6, Smad7 and hepcidin mRNA expression relative to Bmp6mRNAas a ratio in each of HH mouse model, since iron overload in these an-
imals associates with increased hepatic Bmp6 mRNA levels. Whereas
the ratios between Smad6:Bmp6, Smad7:Bmp6 and hepcidin:Bmp6
mRNA levels were similar between Wt mice challenged by systemic
iron injections and dextran-injected control mice (Fig. 2C), we mea-
sured a signiﬁcant decrease of Smad6, Smad7 and hepcidin mRNA ex-
pression in Hfe−/−, TfR2−/−, Hfe/TfR2 double knockout mice and in
Hjv−/− mice (Figs. 2C, 3C, 4C, respectively). Thus, the lack of Hfe,
TfR2, Hfe/TfR2 or Hjv affects the relationship between Smad6, Smad7,
hepcidin and Bmp6 expression. Jointly, our data suggest that Hfe,
TfR2, Hfe/TfR2 and Hjv are not only required for the appropriate
hepcidin mRNA expression but likewise control the mRNA levels of
Smad6 and Smad7.
Importantly, hepcidin1-deﬁcient mice show high mRNA levels of
Bmp6 [24], Smad6 and Smad7 (Fig. 4D; Suppl. Fig. 3D) that is consis-
tent with the response to the severe hepatic iron overload [2] and in-
creased Bmp/Smad signaling in these mice (Suppl. Fig. 4C). In line
with the adequate Bmp6, Smad6 and Smad7 response to iron, the ra-
tios of Smad6:Bmp6 and Smad7:Bmp6 ratio were signiﬁcantly higher
in hepcidin1-deﬁcient mice in regard to control mice (Fig. 4E). Jointly,
our data suggest that signaling pathway(s) affected by the lack of Hfe,
TfR2, Hfe/TfR2 or Hjv proteins rather than hepatic iron levels per se
are critical for the regulation of Smad6, Smad7 and hepcidin mRNA
expression.
3.3. Attenuated Bmp/Smad signaling correlates with low Smad6, Smad7
and hepcidin mRNA expression in HH mouse models
Previous studies suggested that iron and Bmp6 induced hepcidin ex-
pression via phosphorylation of Smad1/5/8 proteins [24,16]. Recent
ﬁndings highlighted the critical importance of the Bmp/Smad signaling
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Fig. 2. Deregulated Smad6, Smad7 and hepcidinmRNA expression inHfe−/−mice. The liver iron content (LIC; μg of iron per gramof dried liver tissue)wasmeasured inHfe−/− (n=19)
and Wt (n=12) mice maintained on C57BL/6J genetic background and fed standard chow until the age of 8–12 weeks (A). Steady-state mRNA expression of Bmp6, Smad6, Smad7 and
hepcidin in Hfe−/−was quantiﬁed by real-time PCR and normalized to the expression of Gapdh. Results are shown as the mean±S.D. (A, B). To provide the relationship between iron
mediated regulation of Smad6, Smad7, hepcidin and Bmp6, weused iron-dextran injectedWtmice (n=5) in comparison to dextran-injectedHfe−/− (n=4) andWt (n=4)mice (C). The
ratios between Smad6, Smad7, or hepcidin to Bmp6mRNA expression were determined individually for each sample and expressed as the mean±S.D. relative to Wt, dextran-injected
mice.
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mouse models and in HFE-HH patients [10–12]. Wemeasured the levels
of pSmad1/5/8 proteins in Wt mice upon systemic iron injections and
observed the anticipated increase in response to iron loading (Suppl.
Fig. 4A,B). By contrast, Hfe−/− mice with high hepatic iron overload
did not show increased pSmad1/5/8 protein levels upon iron injections
when compared to levels measured in control Hfe−/− mice (Suppl.
Fig. 4A,B). This suggests that the attenuated hepatic pSmad1/5/8 levels
in mice with deﬁciencies in Hfe [11,10,13], TfR2 and Hfe/TfR2 [5,13] or
Hjv [15], are responsible for the inappropriate low hepcidin, Smad6 and
Smad7 mRNA expression. Thus, hepcidin, Smad6 and Smad7 mRNA ex-
pression is directly coupled to the activity of the Bmp/Smad signaling
pathway in conditions of genetic iron overload rather than to the hepatic
iron levels per se. By contrast, theHH-associated proteins and the activity
of the Bmp/Smad signaling pathway are dispensable for elevated Bmp6
mRNA expression proposing that the signaling pathways that regulate
hepcidin, Smad6 and Smad7mRNA expression differ from those regulat-
ing Bmp6.
3.4. Systemic iron injections activate Smad6, Smad7 and hepcidin expression
despite the loss of Hfe
We next investigated whether systemic iron injections correlate
with an increase in Smad6, Smad7 and hepcidin mRNA expression and
the activity of Bmp/Smad signaling in the context of Hfe deﬁciency. Re-
peated iron injections in Wt and Hfe−/− mice increased the LIC and
Bmp6 mRNA expression to similar levels (Fig. 5C; Suppl. Fig. 2A,B).However, a concomitant increase of pSmad1/5/8 was not observed in
Hfe−/−mice (Suppl. Fig. 4A,B). In iron-injectedHfe−/−mice, hepcidin
and Smad7 mRNA expression increased by 4.5-fold (pb0.0005) and
2.25-fold (pb0.0003), respectively, as compared to dextran-injected
Hfe−/−mice (Fig. 5B; Suppl. Fig. 2B). Yet the mRNA levels of hepcidin
and Smad7 are lower in iron-loaded Hfe−/− mice compared to the
levels in iron-loaded Wt mice (Fig. 5D), suggesting that Hfe is partially
required for the full hepcidin and Smad7 response during systemic
iron injections. Smad6 mRNA levels increase by 6-fold (pb0.0012) in
iron-loaded Hfe−/− mice relative to the levels in dextran-injected
Hfe−/− controls (Fig. 5B; Suppl. Fig. 2B), and by 1.7-fold (pb0.002) rel-
ative to the levels in iron-treatedWtmice (Fig. 5D). We also measured a
marked increase of Id1, another Bmp/Smad target gene, in response to
iron injections in Wt and in Hfe−/− mice (Fig. 5E; Suppl. Fig. 2D)
being in line with previously published data [13]. The increase in
Smad6, Smad7, hepcidin mRNA levels is unlikely to be explained by in-
creased hepatic Stat3 phosphorylation, which remained unaltered in
iron-loaded Hfe−/− and Wt mice compared to the dextran-injected
controls (Suppl. Fig. 4A). Thus, systemic iron injections in Hfe−/−
mice correlate with the activation of Smad6, Smad7 and hepcidin despite
the lack of concomitant Smad1/5/8 phosphorylation.
Similar results were obtained in Hfe−/−mice raised on FVB genet-
ic background and maintained on iron-rich diet (data not shown).
Whereas hepcidin, Smad6 and Smad7mRNA expression was the lowest
in Hfe/TfR2 double knockout mice in comparison to single mutant mice
(see Fig. 3B) their mRNA expression was raised by several folds upon
iron treatment (Fig. 6A; Suppl. Fig. 3B). Notably, the expression levels
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Fig. 3. Deregulated Smad6, Smad7 and hepcidin mRNA expression in Hfe−/−, TfR2−/− and Hfe/TfR2 mutant mice. The liver iron content (LIC; μg of iron per gram of dried liver
tissue) was analyzed in Wt (n=6) and each of the HH mouse models: Hfe−/− (n=5), TfR2−/− (n=6), and Hfe/TfR2 (n=5) mice (A), all raised on FVB genetic background.
Steady-state mRNA expression of Bmp6, Smad6, Smad7 and hepcidin was quantiﬁed by real-time PCR and normalized to the expression of Gapdh. Results are shown as the
mean±S.D. (A, B). The ratios between Smad6, Smad7 or hepcidin to Bmp6 mRNA expression were determined individually for each sample and expressed as the mean±S.D. rel-
ative to Wt mice (C).
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iron-rich diet (Fig. 6B). This activation occurred even in the absence
of activated Bmp/Smad and Jak/Stat3 signaling cascades [13].
3.5. Overexpression of Smad6 suppresses hepcidin mRNA expression in
primary hepatocytes
Both iSmads quickly respond to signals triggered by Tgf-β family
members and play important roles in a negative feedback regulatory
loop to attenuate Tgf-β/Bmp/Smad signaling. Additionally, iSmads are
critically regulated by iron levels and the activity of the Bmp/Smad sig-
naling pathway (Figs. 1–6). We therefore questioned whether Smad6,like previously shown for the Smad7 [32], can suppress hepcidin
transcription in a dominant way. We overexpressed Smad6 in primary
hepatocytes by adenovirus-mediated gene delivery (AdSmad6 hepato-
cytes). Compared to hepatocytes infected by a control virus (AdLacZ he-
patocytes), hepcidin mRNA expression was suppressed upon Smad6
overexpression under steady-state conditions (Fig. 7A). Even more
strikingly, Smad6 gene delivery completely eliminated hepcidin activa-
tion by Tgf-β treatment (Fig. 7B). Interestingly, mRNA responses of
Smad7 and Id1 were not signiﬁcantly altered in primary hepatocytes
overexpressing Smad6 (AdSmad6 hepatocytes) compared to AdLacZ
Wt primary hepatocytes (Fig. 7A). However, mRNA expression of both
genes was suppressed in Tgf-β treated hepatocytes overexpressing
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Fig. 4. Deregulated Smad6, Smad7 and hepcidinmRNA expression inHjv−/− but not in hepcidin1−/−mutant mice. The liver iron content (LIC; μg of iron per gram of dried liver tissue)
was analyzed in Hjv+/+ (n=8) and Hjv−/− (n=6) mice (A). Steady-state mRNA expression of Bmp6, Smad6, Smad7 and hepcidin in Hjv−/− (A, B), hepcidin1−/− (n=6) and
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Smad6, Smad7 or hepcidin to Bmp6mRNA expression were determined individually for each sample and expressed as the mean±S.D. relative to control mice (C, E).
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Bmp/Smad signaling (i.e. decreased pSmad1 protein levels) as a conse-
quence of Smad6 overexpression (Fig. 7C).
4. Discussion
Inappropriately low hepcidin levels and severe iron accumulation
in the liver are two major hallmarks of HH [32]. Recent data revealed
that physiological hepcidin mRNA expression is maintained by the ac-
tivity of the Bmp/Smad signaling pathway, which is impaired in mice
with mutations in HH-proteins such as Hfe, Hjv, Tfr2, Bmp6, Smad4
and in HFE-HH patients [8–13,16–18]. Using mouse models for HH
and iron-loaded Wt mice, we now show that two feed-back regula-
tors of Tgf-β/Bmp/Smad-signaling are responsive to iron-levels and
are co-regulated with hepcidin via the Bmp/Smad signaling pathway.Our data demonstrate that Smad6, Smad7 andhepcidinmRNAexpres-
sion is increased together with liver iron levels when the Bmp/Smad sig-
naling pathway is intact. Deﬁciency of the HH-associated membrane
proteins that are involved in the surveillance of systemic iron levels atten-
uates Bmp/Smad signaling as well as Smad6, Smad7 and hepcidin mRNA
expression. This suggests that each of the HH proteins (Hfe, TfR2, and
Hjv) is critical to maintain the responses of Smad6, Smad7 and hepcidin
to iron levels. Of note is that mice with a combined loss of Hfe and TfR2
proteins show the lowest hepatic Smad6, Smad7 andhepcidin levels com-
pared to mice with the loss of either gene individually (Fig. 3). We sus-
pect that Hfe and TfR2 either act as a complex and/or employ multiple
signaling pathways that synergistically inﬂuence the expression of the re-
sponsive genes. Our observations inmice are partially reﬂected upon by a
study of non-venesected Hfe-HH patients, in which a signiﬁcantly higher
Smad6 mRNA expression compared to systemic iron levels and the
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Fig. 5. Systemic iron injections inHfe−/−mice cause increased hepatic iron levels and induction of Bmp6, Smad6, Smad7 and hepcidinmRNA expression.Wt (n=5) andHfe−/− (n=5)
mice were subjected to repeated iron-dextran injections over a period of 3 weeks. In parallel 4 Wt and 4 Hfe−/−mice were injected with dextran solution only. Mice were sacriﬁced at
the age of 8 weeks and analyzed for hepatic iron content (LIC; indicated as μg of iron per g of dried liver tissue) (A, C). The mRNA expression of Bmp6 (A, C), hepcidin, Smad7 and Smad6
mRNA (B, D) and Id1 (E) was quantiﬁed by real-time PCR and expressed relative to GapdhmRNA expression as the mean±S.D.
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studies reportedweaker or absent induction of Smad7 in Hfe-HHpatients
[33,12] suggesting that the difference in the magnitude of Smad6 and
Smad7 responsemaybe due to differences in a patients' diet, demograph-
ic status, gender, medical status or genetically determined set point for
iron stores.
Equally interesting is ourﬁnding that stimuli known to affect hepcidin
expression also control Smad6 and Smad7 levels, yet in amanner not cor-
relating with the activity of the Bmp/Smad signaling pathway. For exam-
ple, systemic iron injections of Hfe−/−mice increase hepatic iron stores
without a concomitant increase of pSmad1/5/8 (Suppl. Fig. 4). Under thiscondition, Smad6, Smad7 and hepcidin expression is signiﬁcantly
upregulated. Likewise, dietary iron loading of mice with a combined
loss ofHfe and TfR2 resulted in a signiﬁcant increase of Smad6, Smad7 and
hepcidin expression (Fig. 6), bypassing the activation of a Bmp/Smad
signaling cascade [13]. While currently we cannot fully exclude that
unaltered pSmad1/5/8 levels under the conditions of systemic iron load-
ing in Hfe or Hfe/TfR2 mice may be explained by subtle increases of
pSmad1/5/8 that cannot be detected byWestern blot analysis or by tran-
sient kinetics that differ from target gene expression, our data support
the view shared by other investigators that other, yet to be discovered al-
ternative signaling pathway(s) exist to communicate chronically high
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Fig. 6. Smad6, Smad7 and hepcidin mRNA expression in Hfe/TfR2 mutant mice upon dietary iron loading. Mice with combined loss of Hfe and TfR2 (Hfe/TfR2mice) were maintained
on iron balanced (n=5) or on a high-iron diet (n=3) containing 25,000 ppm iron as previously described [13]. Four Wt mice were maintained on the same iron-rich diet. All mice
were raised on FVB genetic background. Liver Smad6, Smad7 and hepcidin mRNA expression were quantiﬁed by real time PCR and normalized to GapdhmRNA. Data are expressed
as the mean±S.D. in Hfe/TfR2 mice fed an iron-rich diet in regard to (A) Hfe/TfR2 mice fed an iron-balanced diet or (B) Wt mice fed an iron-rich diet.
83M. Vujić Spasić et al. / Biochimica et Biophysica Acta 1832 (2013) 76–84iron levels to hepcidin [13,34] and to Smad6, Smad7 and Id1. This action is
independent of Hfe and Hfe/TfR2.
The striking co-regulatory expression pattern of Smad6 and Smad7
in mouse models of iron overload and the ﬁndings that Smad7
overexpression suppresses hepcidin in vitro [26], led us to question
whether a relationship between Smad6 and the regulation of hepcidin
may exist. We show that overexpression of Smad6 in murine primary
hepatocytes inhibits hepcidin expression (Fig. 7A). Even more strik-
ingly, Smad6 gene delivery completely eliminates hepcidin activation2.5
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Fig. 7. Smad6 overexpression suppresses hepcidin mRNA levels in primary hepatocytes. Prim
ing the full length murine Smad6 gene under the control of the CMV promoter (AdSmad6) or
untreated or treated with TGFβ and harvested for RNA and protein isolation. (A, B) mRNA e
normalized to the expression of Gapdh. Results are shown as the mean±S.D. (C) The levels
analysis.by TGFβ, a potent inducer of liver ﬁbrosis (Fig. 7B). Themechanism by
which the two inhibitory Smads, Smad6 and Smad7 control Hepcidin
mRNA expression differs. Smad7 overexpression in primary hepato-
cytes strongly decreases Smad1 and Smad2/3 phosphorylation, that
links to Bmp and TGFβ ligands, respectively [26]. On the other hand,
Smad6 affects hepcidin suppression by inhibiting the phosphoryla-
tion of Smad1 (and not Smad2/3) (Fig. 7C). Possibly, additional regu-
latory modes may be operational such as binding to cognate SMAD
regulatory motif GTCAAGAC within the hepcidin promoter [26], or16.0
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ary hepatocytes from C57/BL6 mice were transduced with adenoviral vectors express-
with adenoviral vectors encoding β-galactosidase as a control (AdLacZ). Cells were left
xpression of hepcidin, Id1 and Smad7 was analyzed by quantitative real-time PCR and
of pSmad1, pSmad2 and pSmad3 and β-actin proteins were analyzed by Western blot
84 M. Vujić Spasić et al. / Biochimica et Biophysica Acta 1832 (2013) 76–84through SMAD4 degradation [35]. We propose that Smad6 and Smad7
may therefore constitute novel layers of hepcidin regulation.
5. Conclusions
In this study we deﬁne the mRNA expression of Smad6 and Smad7
within pathways known to regulate hepcidin levels. Dietary iron or sys-
temic iron injections trigger co-ordinated increase in hepcidin, Smad6
and Smad7 mRNA expression, the response that is however abolished
in mice with genetic iron overload due to mutation in Hfe, TfR2, Hfe/
TfR2, or Hjv. We thus conclude that Smad6, Smad7 and hepcidin mRNA
expression correlates with the activity of the Bmp/Smad signaling path-
way rather than with liver iron levels. Interestingly, this regulatory cir-
cuitry is uncoupled by iron treatment ofHfe−/− andHfe/TfR2mice, that
results in a signiﬁcant increase of hepcidin, Smad6 and Smad7mRNA ex-
pression being suggestive that additional regulatory mechanisms con-
tribute to their regulation which do not exclusively require Hfe. When
overexpressed in cells, the inhibitory Smad6 and Smad7 suppress
hepcidin mRNA levels suggesting that conditions hallmarked by high
levels of Smad6 and Smad7 may be linked to altered iron homeostasis
via Smad6 or Smad7 mediated hepcidin suppression.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2012.08.013.
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